ClinicalTrials.gg
RecruitingNCT07259226OASISUpdated Dec 2, 2025

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

A Phase 2 interventional study of Biological samples collection and questionnaires to collect patient reported outcomes in Advanced Breast Cancer, Advanced Gastric Cancer and Advanced Urothelial Cancer, sponsored by UNICANCER. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by UNICANCER · Phase 2, Interventional, and Basic science

How we know · 6 judgments

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Breast Neoplasms by UNICANCER — 15 open to participants now, 27 under way, 7 of them phase 3. Breast Neoplasms · UNICANCER.

Planned enrollment
18th of 59
400 · median 170
Started
2025
with 4 others
Phase 2
28 of 64
8 open now
Primary completion
2030-11
later than 18 of 26 live
Registered
60th of 64
by date

Among the 64 studies in Breast Neoplasms by UNICANCER, this one is the 18th largest by planned enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2025, is one of 28 in phase 2, reaches primary completion later than 18 of the 26 other live ones, and was the 60th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 64 studies in Breast Neoplasms by UNICANCER are open now, in 9 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by UNICANCER, or all of them as a file.
02

Study summary

International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types.

Read the detailed description

Over the past five years, antibody-drug conjugates (ADCs) have dramatically improved survival in solid and hematologic malignancies. Among 14 ADCs approved worldwide, nine are now available in Europe, and over 370 others are in clinical development. This expanding landscape indicates that ADCs could soon replace conventional chemotherapy across multiple tumor types. Given this rapid evolution, clinicians will need to select the most suitable ADC for each patient, considering tumor biology, microenvironment (TME) and patient-specific factors. Yet, despite remarkable efficacy, resistance to ADCs eventually arises. Understanding resistance mechanisms is therefore essential to guide therapeutic sequencing and optimize next-generation ADCs.

ADCs are complex molecules combining an antibody, a linker, and a cytotoxic payload. Their activity depends on factors such as antigen expression, internalization, linker stability, and payload sensitivity. Resistance can result from altered vascular perfusion, antigen downregulation, defective internalization or trafficking, impaired linker cleavage, drug efflux, or payload target modifications. These multifactorial processes differ from those driving resistance to traditional chemotherapies. Existing preclinical and clinical tools (Patient-Derived Xenograft(PDX)/Cell-line-Derived Xenograft (CDX) models, standard imaging, Immunohistochemistry (IHC), genomic profiling) fail to capture this complexity or predict ADC efficacy and resistance. Furthermore, ADCs often cause significant toxicities-on-target or off-target-affecting the ocular surface, skin, lungs, and peripheral nerves. Patient factors such as age, comorbidities, and weight influence these events. Understanding the determinants of toxicity is critical to maintain quality of life and treatment adherence.

The OASIS program aims to identify predictive biomarkers of ADC response and toxicity to enable personalized ADC selection and toxicity prevention. This multicenter study will integrate advanced technologies-digital pathology, liquid biopsy, and Patient-derived organoids (PDOs)-to generate comprehensive biological and clinical data. Using these datasets, a multimodal machine-learning model (OASIS Multiparametric Score) will be developed to predict both efficacy and key toxicities of ADCs. The project will prospectively include patients receiving ADCs in standard practice, with longitudinal tumor and blood sampling to investigate biomarkers of resistance and toxicity. In parallel, preclinical models derived from patient tumors will explore resistance mechanisms and screen ADC sensitivity.

A retrospective cohort of patients previously treated with ADCs will first be analyzed to prioritize biomarker candidates based on published data and prior findings. From this, five binary biomarkers will be selected for the primary objective. Combined with prospective data, this retrospective work will expand the translational biobank and support the construction of the OASIS score.

03

Conditions studied

  • Advanced Breast Cancer
  • Advanced Gastric Cancer
  • Advanced Urothelial Cancer
  • Advanced Non Small Cell Lung Cancer (NSCLC)

Keywords

  • ADC
  • resistance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have signed a written form prior to any trial specific procedures;
  2. Patients must be ≥18 years old;
  3. confirmed or radiologically documented unresectable locally advanced or cancer (Breast, Urothelial, Non small Cell Lung or Gastric) with an indication to receive an Antibody-Drug Conjugate (ADC) approved or accessible through an early access program;
  4. Patients must have at least 2 tumor lesions (primary tumor can be included): at least one measurable tumor lesion for tumor evaluation according to (RECIST) V1.1 and at least one tumor lesion other than bone and brain for ;
  5. Patients must have a metastatic or locally advanced tumor site easily accessible to biopsy (with exception of bone and ) and must have agreed to perform pretreatment and post-treatment biopsies; an archival pre-treatment biopsy may be used if it was collected within one month of enrolment, if no anticancer therapy was administered after the biopsy and if sufficient material is available for research;
  6. must be ≥12 weeks according to the discretion of the investigator;
  7. performance status ≤ 2;
  8. Patients must have adequate hematologic and organ function, compatible with ADC administration, as per drug-specific recommendations;
  9. Women of and male patient must agree to use adequate for the duration of trial participation and up to 7 months after completing treatment for women and up to 4 months for men;
  10. Patients must be affiliated to a social security system (or equivalent);
  11. Patients must be willing and able to comply with the protocol for the duration of the trial;
  12. Patients must consent to the use of their collected tumor specimen, as well as, blood samples as detailed in the protocol for future scientific research, which includes but is not limited to DNA, RNA, and protein-based biomarker analysis.

Exclusion criteria

Exclusion Criteria:

  1. Patients treated with an antibody drug conjugate in a curative setting;
  2. Patients who did not consent to sample use;
  3. Presence of another progressive pathology with short-term life-threatening prognosis;
  4. Patients undergoing concurrent treatment for a or hematologic disorder distinct from the indication for which the ADC is being administered.
  5. Patients with inadequate prior to Cycle 1 Day 1, defined as:

    • Whole brain radiation therapy \<14 days or stereotactic brain radiation therapy \<7 days.
    • Any cytotoxic chemotherapy, agents or other anticancer drug(s) (including another ADC) from a previous cancer treatment regimen or clinical study (other than epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)), \<14 days or 5 half-lives, whichever is longer.
    • therapy \<21 days.
    • Hormonal therapy \<21 days.
    • Major surgery (excluding placement of vascular access) \<28 days.
    • Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation \<28 days or palliative radiation therapy \<14 days.
  6. Female participant who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 90 days after the final administration of study treatment;
  7. Person deprived of their liberty or under protective custody or guardianship.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Other
    T-DXd (trastuzumab deruxtecan)

    Standard of care T-DXd indication

    Procedure: Biological samples collection · Behavioral: questionnaires to collect patient reported outcomes

  • Other
    T-DM1 (trastuzumab emtansine)

    Standard of care T-DM1 indication

    Procedure: Biological samples collection · Behavioral: questionnaires to collect patient reported outcomes

  • Other
    SG (sacituzumab govitecan)

    Standard of care SG indication

    Procedure: Biological samples collection · Behavioral: questionnaires to collect patient reported outcomes

  • Other
    EV (enfortumab vedotin)

    Standard of care EV indication

    Procedure: Biological samples collection · Behavioral: questionnaires to collect patient reported outcomes

Interventions

  • ProcedureBiological samples collection

    Biological samples collection (tumor tissue, blood, sputum) before initiation of treatment, during treatment, and at treatment discontinuation.

    Also known as: Blood sample collection, Sputum sample collection, Tumor tissue sample collection

  • Behavioralquestionnaires to collect patient reported outcomes

    QLQ-C30, QLQ-FA12, HADS, EQ-5D 5L

This study also gives Trastuzumab deruxtecanStudies of Trastuzumab deruxtecanTrastuzumab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., Sacituzumab govitecanStudies of Sacituzumab govitecanSacituzumab govitecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., Enfortumab vedotinStudies of Enfortumab vedotinEnfortumab vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., Ado-Trastuzumab EmtansineStudies of Ado-Trastuzumab EmtansineAdo-Trastuzumab Emtansine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Biomarkers of resistance to ADC

    Resistance is defined by differences in the frequency (higher or lower) of molecular aberrations detected between paired baseline samples and progression samples (i.e., samples collected at the time of disease progression under ADC treatment)

    Time frame: Through study completion, an average of 3 years

Secondary outcomes

  1. Additional biomarkers of resistance characterised by histology

    Differences in the frequency of molecular aberrations characterised by histologic/proteomic/genomic/transcriptomic analysis between samples of patients progressing on ADC and paired pre-treatment samples (beyond biomarkers of primary outcome)

    Time frame: Through study completion, an average of 3 years

  2. Biomarkers of ADC outcome

    Progression-Free Survival (PFS) defined as the time from start of treatment and radiological progression or death, whichever occurs first. Tumor assessments are made by local investigators as per standard practice (RECIST 1.1.). Patients still alive at the cut-off time without documented progression (including lost to follow-up) will be censored at the time of latest evaluable efficacy assessment.

    Time frame: From first day of cycle 1 (each cycle is 21 to 28 days) to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

  3. Biomarkers of ADC outcome

    Objective Response Rate (ORR) defined as the proportion of patients with a confirmed complete response (CR) or partial response (PR) assessed by investigators after 6 months of treatment.

    Time frame: From first day of cycle 1 (each cycle is 21 to 28 days) to date of 6 months of treatment completion

  4. Biomarkers of ADC outcome

    Clinical Benefit Rate (CBR) defined as the proportion of patients who had a CR, PR, or stable disease for 6 months or more.

    Time frame: From first day of cycle 1 (each cycle is 21 to 28 days) to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

  5. Biomarkers of resistance to ADC

    Duration of response (DOR) defined as the time from treatment initiation to disease progression or death for patients who achieve CR or PR.

    Time frame: From first day of cycle 1 (each cycle is 21 to 28 days) to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

  6. Biomarkers of ADC outcome

    Overall Survival (OS) defined as the time from inclusion to death due to any cause. Patients still alive at the cut-off time (including lost to follow-up) will be censored at the last known alive date.

    Time frame: From first day of cycle 1 (each cycle is 21 to 28 days) to date of death from any cause, assessed up to 60 months

  7. Expression of ADC target measured on CTC and within tumor tissue

    Concordance between ADC target expression (HER2, TROP-2, Nectin-4) on pre- and post-treatment tumor biopsy (IHC) and antigen expression on Circulating Tumor Cells (CTCs).

    Time frame: Through study completion, an average of 3 years

  8. Patients' reported outcomes (PROs)

    Overall quality of life will be assessed using the EORTC-QLQ-C30 and EQ-5D-5L at Baseline, after 3 months of treatment completion, at treatment discontinuation (for progression or any other reason)

    Time frame: Through study completion, an average of 3 years

  9. Patients' reported outcomes (PROs)

    Fatigue will be assessed using QLQ-FA12 at Baseline, after 3 months of treatment completion, at treatment discontinuation (for progression or any other reason).

    Time frame: Through study completion, an average of 3 years

  10. Patients' reported outcomes (PROs)

    Anxiety and depression will be assessed using HADS questionnaire at Baseline, after 3 months of treatment completion, at treatment discontinuation (for progression or any other reason)

    Time frame: Through study completion, an average of 3 years

  11. Treatment cost

    Number of resources consumed in terms of treatment, hospitalization (for drug administration and toxicity), biological and radiological exams during the ADC treatment, in order to calculated the corresponding management cost.

    Time frame: Through study completion, an average of 3 years

  12. ADC-related specific toxicities

    Safety as measured by the frequency and severity of key ADC toxicity (Interstitial Lung Disease, skin toxicity, ocular toxicity, peripheral neuropathy) as measured by NCI-CTCAE v 5.0.

    Time frame: Through study completion, an average of 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2030, 59 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 59 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Dec 2, 2025
StartActual
Nov 14, 2025
Primary completionEst.
Nov 1, 2030
CompletionEst.
Nov 1, 2030
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07259226
Lead sponsor
UNICANCER
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Nov 14, 2025
Primary completion
Nov 1, 2030 (estimated)
Completion
Nov 1, 2030 (estimated)
Last update
Dec 2, 2025

Study contacts

Marjorie Mauduit
Contact
m-mauduit@unicancer.fr
+33 6 30481792
Jérôme Lemonnier
Contact
j-lemonnier@unicancer.fr
Barbara Pistilli, MD, PhD
principal investigator · Gustave Roussy Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion